Comparative Pharmacology
Head-to-head clinical analysis: BRIVIACT versus LYRICA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRIVIACT versus LYRICA.
BRIVIACT vs LYRICA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brivaracetam is a synaptic vesicle glycoprotein 2A (SV2A) ligand with high affinity. The exact mechanism by which it exerts its antiepileptic effect is unknown, but binding to SV2A is thought to modulate neurotransmitter release.
Binds to the α2-δ subunit of voltage-gated calcium channels, reducing calcium influx and inhibiting release of excitatory neurotransmitters including glutamate, norepinephrine, and substance P.
50 mg orally twice daily; may increase up to 100 mg twice daily based on response and tolerability.
Oral: 75-150 mg twice daily or 50-100 mg three times daily; maximum 600 mg/day. Start at 75 mg twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 9 hours (range 7–11 hours). This supports a twice-daily dosing regimen (e.g., 50 mg twice daily) with steady state achieved within approximately 2 days.
Terminal elimination half-life is 6.3 hours (range 5.5–6.7 hours) in patients with normal renal function. Half-life increases in renal impairment (up to 48 hours in anuria).
Approximately 95% of the dose is excreted in urine as metabolites or unchanged drug (<1% unchanged). About 0.8% is excreted in feces via biliary elimination.
Renal excretion of unchanged drug accounts for approximately 90% of elimination; less than 1% is secreted in feces or bile. Dose adjustment required in renal impairment (CrCl <60 mL/min).
Category C
Category C
Anticonvulsant
Anticonvulsant